Mitotane Side Effects: Understanding Key Risks in Adrenocortical Carcinoma Therapy

　　Mitotane is the most widely used adrenolytic agent in the pharmacological management of adrenocortical carcinoma(ACC).Its mechanism of action combines direct cytotoxic effects with selective destruction of adrenal cortical tissue.This distinctive pharmacological profile results in an adverse-event spectrum that differs markedly from that of conventional anticancer agents.Beyond common toxicities affecting the gastrointestinal and nervous systems,mitotane profoundly disrupts adrenal hormone synthesis and metabolism,giving rise to a range of endocrine-related complications.A thorough understanding of these side effects is essential for safeguarding treatment safety and preserving patient quality of life.

　　Gastrointestinal disturbances represent the most frequent early adverse events associated with mitotane.During the initial phase of therapy,the majority of patients experience varying degrees of anorexia,nausea,vomiting,diarrhea,and abdominal discomfort.These symptoms are attributed to both direct mucosal irritation and central nervous system effects of the drug.If gastrointestinal reactions persist or worsen,patients may face difficulties with adequate oral intake,leading to nutritional compromise and weight loss.Clinical management typically includes taking the medication with meals,adopting a small and frequent meal pattern,and using antiemetic agents when necessary.Dose adjustment or temporary treatment interruption may be considered based on symptom severity.

　　Neurological and systemic reactions also warrant careful attention.Some patients may develop dizziness,somnolence,fatigue,headache,reduced concentration,and impaired motor coordination during mitotane therapy.These manifestations are related to the drug's suppressive effects on the central nervous system and tend to be more pronounced during the early treatment period as plasma levels gradually rise.When symptoms are significant,they may impair daily functioning and pose safety risks,particularly for activities requiring alertness such as driving.Additionally,a subset of patients may experience dermatological reactions such as rash,as well as metabolic changes including dyslipidemia.Individual variability in these responses is considerable,underscoring the need for personalized assessment.

　　Adrenocortical insufficiency is the most distinctive and clinically critical risk of mitotane therapy.By selectively destroying adrenal cortical cells,mitotane inevitably compromises the gland's capacity to synthesize cortisol and aldosterone.As treatment progresses,patients may develop progressive signs of glucocorticoid and mineralocorticoid deficiency,including profound fatigue,orthostatic hypotension,markedly reduced appetite,worsening nausea and vomiting,and hyponatremia.If unrecognized and untreated,severe cases may progress to adrenal crisis,a life-threatening emergency.Consequently,glucocorticoid replacement therapy(typically hydrocortisone)is routinely co-administered throughout mitotane treatment,and regular monitoring of morning cortisol,adrenocorticotropic hormone(ACTH),and electrolyte levels is essential.Importantly,mitotane accelerates the metabolic clearance of exogenous glucocorticoids,meaning that replacement doses often need to exceed those used in standard adrenal insufficiency management—a critical consideration in clinical practice.

　　Hepatic function changes constitute another important monitoring parameter during mitotane therapy.Mitotane undergoes hepatic metabolism,and prolonged use may lead to elevated transaminases,abnormal bilirubin levels,and other hepatic alterations.Although these changes are usually mild to moderate and reversible,periodic liver function testing is recommended throughout treatment to enable early detection and timely intervention.Furthermore,mitotane has an exceptionally long elimination half-life ranging from several weeks to months,meaning its effects may persist well beyond treatment discontinuation.This pharmacokinetic property necessitates continued monitoring of relevant parameters for a period after therapy cessation.

　　In summary,the management of mitotane-related side effects is a multidimensional and dynamic process.Mild gastrointestinal discomfort and fatigue are common and generally manageable with supportive measures.In contrast,adrenocortical insufficiency,significant neurological symptoms,and hepatic abnormalities are adverse events that demand heightened vigilance,rigorous laboratory surveillance,and prompt clinical intervention.Patients receiving mitotane therapy should adhere strictly to their care team's follow-up schedule,completing regular assessments of drug plasma levels,adrenal function,hepatic function,and lipid profiles to ensure that treatment proceeds safely within a well-controlled framework.